Confirmed Safety of Deutetrabenazine for Tardive Dyskinesia in a 2-Year Open-Label Extension Study

被引：0
|
作者：
Fernandez, Hubert H. [1 ]
Stamler, David [2 ]
Davis, Mat D. [2 ]
Factor, Stewart A. [3 ]
Hauser, Robert A. [4 ]
Jimenez-Shahed, Joohi [5 ]
Ondo, William G. [6 ,7 ]
Jarskog, L. Fredrik [8 ]
Woods, Scott W. [9 ]
LeDoux, Mark S. [10 ]
Shprecher, David R. [11 ]
Anderson, Karen E. [12 ]
机构：
[1] Cleveland Clin, Ctr Neurol Restorat, Cleveland, OH 44106 USA
[2] Teva Pharmaceut Ind, La Jolla, CA USA
[3] Emory Univ, Sch Med, Atlanta, GA 30322 USA
[4] Movement Disorders Ctr, Tampa, FL USA
[5] Parkinsons Dis Ctr & Movement Disorders Clin, Houston, TX USA
[6] Methodist Neurol Inst, Houston, TX USA
[7] Weill Cornell Med Coll, Houston, TX USA
[8] Univ North Carolina, Sch Med, Chapel Hill, NC 27515 USA
[9] Yale Sch Med, New Haven, CT USA
[10] Univ Tennessee, Ctr Hlth Sci, Memphis, TN 38163 USA
[11] Banner Sun Hlth Res Inst, Sun City, AZ USA
[12] Georgetown Univ, Washington, DC USA
来源：
NEUROLOGY | 2018年 / 90卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P4.075
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Long-Term Deutetrabenazine Treatment for Tardive Dyskinesia Is Associated With Sustained Benefits and Safety: A 3-Year, Open-Label Extension Study
    Hauser, Robert A.
    Barkay, Hadas
    Fernandez, Hubert H.
    Factor, Stewart A.
    Jimenez-Shahed, Joohi
    Gross, Nicholas
    Marinelli, Leslie
    Wilhelm, Amanda
    Alexander, Jessica
    Gordon, Mark Forrest
    Savola, Juha-Matti
    Anderson, Karen E.
    FRONTIERS IN NEUROLOGY, 2022, 13
  • [2] The Safety of Deutetrabenazine for Chorea in Huntington Disease: An Open-Label Extension Study
    Samuel Frank
    Claudia Testa
    Mary C. Edmondson
    Jody Goldstein
    Elise Kayson
    Blair R. Leavitt
    David Oakes
    Christine O’Neill
    Christina Vaughan
    Jacquelyn Whaley
    Nicholas Gross
    Mark Forrest Gordon
    Juha-Matti Savola
    CNS Drugs, 2022, 36 : 1207 - 1216
  • [3] The Safety of Deutetrabenazine for Chorea in Huntington Disease: An Open-Label Extension Study
    Frank, Samuel
    Testa, Claudia
    Edmondson, Mary C.
    Goldstein, Jody
    Kayson, Elise
    Leavitt, Blair R.
    Oakes, David
    O'Neill, Christine
    Vaughan, Christina
    Whaley, Jacquelyn
    Gross, Nicholas
    Gordon, Mark Forrest
    Savola, Juha-Matti
    CNS DRUGS, 2022, 36 (11) : 1207 - 1216
  • [4] Deutetrabenazine Reduces Involuntary Movements in Patients Most Severely Impacted by Tardive Dyskinesia in a 3-year Open-Label Extension Trial
    Bona, J.
    Barkay, H.
    Wilhelm, A.
    Chaijale, N.
    Gordon, M.
    MOVEMENT DISORDERS, 2020, 35 : S31 - S32
  • [5] Long-Term Treatment With Deutetrabenazine Is Associated With Continued Improvement in Tardive Dyskinesia: Results From an Open-Label Extension Study
    Hauser, R.
    Barkay, H.
    Fernandez, H.
    Factor, S.
    Jimenez-Shahed, J.
    Gross, N.
    Gordon, M.
    Savola, J. M.
    Anderson, K.
    MOVEMENT DISORDERS, 2019, 34 : S596 - S596
  • [6] Levetiracetam in tardive dyskinesia: an open-label study
    Pappa, S
    Tsironis, C
    Mantas, C
    Konitsiotis, S
    JOURNAL OF NEUROLOGY, 2005, 252 : 120 - 120
  • [7] Long-term safety of deutetrabenazine for the treatment of tardive dyskinesia: Results from an open-label, long-term study
    Anderson, K.
    Stamler, D.
    Davis, M.
    Factor, S.
    Hauser, R.
    Isojarvi, J.
    Jarskog, L.
    Jimenez-Shahed, J.
    Kumar, R.
    Ochudlo, S.
    Ondo, W.
    Fernandez, H.
    MOVEMENT DISORDERS, 2017, 32
  • [8] Long-Term Treatment With Deutetrabenazine is Associated With Continued Improvement in Tardive Dyskinesia (TD): Results From an Open-Label Extension Study
    Hauser, Robert A.
    Fernandez, Hubert H.
    Stamler, David
    Davis, Mat D.
    Factor, Stewart A.
    Jimenez-Shahed, Joohi
    Ondo, William G.
    Jarskog, L. Fredrik
    Woods, Scott W.
    LeDoux, Mark S.
    Shprecher, David R.
    Anderson, Karen E.
    NEUROLOGY, 2018, 90
  • [9] Long-Term Treatment With Deutetrabenazine Is Associated With Continued Improvement in Tardive Dyskinesia (TD): Results From an Open-Label Extension Study
    Hauser, Robert
    Barkay, Hadas
    Fernandez, Hubert
    Factor, Stewart
    Jimenez-Shahed, Joohi
    Gross, Nicholas
    Savola, Juha-Matti
    Anderson, Karen E.
    NEUROLOGY, 2019, 92 (15)
  • [10] Safety and effectiveness of lurasidone in adolescents with schizophrenia: results of a 2-year, open-label extension study
    Correll, Christoph U.
    Findling, Robert L.
    Tocco, Michael
    Pikalov, Andrei
    Deng, Ling
    Goldman, Robert
    CNS SPECTRUMS, 2022, 27 (01) : 118 - 128
12345